Sbir phase i: automated clot preventing chest tube

This $256,000 National Science Foundation project grant supports the development of an automated chest tube to prevent clotting. Circulatech LLC will design and prototype a novel chest tube that proactively manages fluid flow within the catheter lumen to flush and drain the tube, reducing blood clot formation. Through a process called "dilutional coagulopathy," the tube will use sterile saline or anticoagulants to reduce thrombosis in the drainage space rather than relying on chemical or mechanical barriers. The company will develop prototypes using biomaterials and fabrication methods suitable for eventual patient use and demonstrate proof of concept and reduced clotting in an animal model of post-surgical drainage complications. This award falls under the NSF Technology, Innovation, and Partnerships program to advance science, engineering, and innovation leading to breakthrough technologies and solutions to national challenges.

Abstract

This small business innovation research (sbir) phase i project aims to develop strategies to mitigate occlusion of thoracic catheters (chest tubes). A study by the cleveland clinic determined that 36% of chest tubes were completely obstructed at one point, with 86% of these clots existing in the thoracic cavity, undetected by clinicians. The complications that result from occluded chest tubes can include postoperative atrial fibrillation, hemothorax, and cardiac tamponade. The team will design, develop, and commercialize a novel chest tube to solve the high impact clinical need. This novel chest tube seeks to reduce drainage-related complications following cardiothoracic surgery. The novel system proactively manages fluid flow within the inner lumen of a catheter in order to flush and drain the tube, reducing the incidence of blood clogging. The proposed activity seeks to develop a chest tube that proactively provides fluid flow in order to prevent blood clot formation associated with draining fluid and blood during cardiovascular surgery. The product introduces a novel approach called dilutional coagulopathy for addressing clotting issues, where sterile saline or anticoagulants is proactively used to reduce thrombosis in an enclosed drainage spaces, rather than rely on historical methods of chemical or mechanical barriers for reducing or hindering clot formation. The project aims to develop prototypes using biomaterials and fabrication methods suitable for eventual patient use, and undertake the risks of demonstrating proof of concept and reduced clotting in an animal model of post-surgical drainage complications. This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the foundation's intellectual merit and broader impacts review criteria.